BioElectronics Executes Distribution Agreement with KT Health, LLC for North American Retail Market FREDERICK, MD, Dec. 15, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — BioElectronics Corporation (OTC PINK: BIEL), (www.bielcorp.com) is pleased to announce that it has executed an OEM agreement with KT Health, LLC to bring its innovative pain management devices to encompass retail and e-commerce distribution throughout North America, as well as several additional key international markets.
The agreement incorporates BioElectronics’ ActiPatch® technology into KT Health’s KT Recovery+® product line, which will be marketed under the proprietary trade name KT Recovery+ Wave™. KT Health will leverage BioElectronics’ FDA 510(k) clearance to market, promote, and distribute the devices for the treatment of general musculoskeletal pain. As part of this agreement BioElectronics will cease active promotion of the brand name ActiPatch in North America. Existing channel partners in the USA will continue promoting the ActiPatch brand name, while BioElectronics will continue expanding its network of international distributors for ActiPatch.
Keith Nalepka, VP Sales and Marketing for BioElectronics, said, “This is an amazing win for our Company. KT Recovery+ Wave™ combines our drug-free pain relief technology with the brand power and adhesives expertise of the recognized leader in drug-free pain treatment and recovery. Consumers will be able to easily place the KT Recovery+ Wave™ device anywhere on the body to treat musculoskeletal pain. We believe KT Health is an excellent match for our technology and can effectively leverage its large customer base that is already comfortable with wearables.”
Greg Venner, CEO of KT Health, commented, “We are extremely pleased to be partnering with BioElectronics on such an innovative and effective product. KT Recovery+ Wave™ allows KT Health to broaden our drug-free pain relief options, expanding our product line into the chronic pain category. We look forward to a long and productive partnership with BioElectronics.”
About BioElectronics Corporation:
Headquartered in Frederick, Maryland, and founded in 2000, BioElectronics Corporation is the leading company in the field on non-invasive electroceutical medical devices. BioElectronics is the maker of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Therapy for postoperative pain and chronic wound care.
About KT Health, LLC:
Based in American Fork, Utah and founded in 2008, KT Health, LLC has revolutionized sports medicine with some of the most advanced drug-free pain relief and recovery products in the industry. KT Health’s products have become the athlete’s choice for drug free pain relief and injury management. The Company currently designs, develops, and distributes a variety of kinesiology tape lines, including KT Tape® Original (cotton) and KT Tape® Pro™ (synthetic), as well as a line of performance and recovery products. KT Health is the largest kinesiology tape manufacturer in the world, available in 42,000+ domestic retail locations and 40 countries. For more information, visit www.kttape.com.
Forward Looking Statements:
Certain information set forth in this email contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business, projects, and joint ventures; (iv) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company’s projects; (vi) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (vii) renewal of the Company’s current customer, supplier and other material agreements; and (viii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.
These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this email are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.